NCT00048360

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 162 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Conditions

• Attention Deficit Disorder

Interventions

Type	Name	Description
DRUG	Extended-release bupropion hydrochloride

Timeline

• Start date: 2002-10-01
• Primary completion: 2003-06-01
• Completion: 2003-06-01
• First posted: 2002-10-31
• Last updated: 2013-02-12

Locations

21 sites across 1 country: United States